MetaCap

Monte Rosa Therapeutics (GLUE) vs Prime Medicine (PRME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prime Medicine (PRME) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, losing 2.2% versus a loss of 39.2%. Prime Medicine is the larger company by market cap ($791.6 million vs $738.3 million), about 1.1 times the size, while Monte Rosa Therapeutics is growing revenue faster (+63.5% vs +55.3%). Monte Rosa Therapeutics converts more of its revenue into profit, with a net margin of -31.2% versus -4342.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GLUE-39.24%PRME-2.20%
+84%+19%-45%
Nov 21, 20251 yearNov 20, 2026
GLUE+11.05%PRME-77.47%
+231%+62%-108%
Oct 17, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GLUE versus PRME key metrics
MetricGLUEPRME
Share price$8.64$3.55
Market cap$738.29M$791.62M
1-day change-3.03%-7.55%
YTD return-44.90%+2.31%
1-year return-39.24%-2.20%
5-year return-57.96%—
EPS (TTM)$-1.39$-0.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$123.67M$4.63M
Revenue growth (YoY)+63.54%+55.28%
Net income (latest FY)$-38.60M$-201.14M
Operating margin-43.83%-4498.06%
Net margin-31.21%-4342.44%
52-week high$25.77$5.91
52-week low$8.48$2.67
Distance from 52-week high-66.47%-39.93%
Analyst consensusstrong_buybuy
Avg. price target upside+193.75%+108.17%
Average volume1.37M4.64M
Shares outstanding85.45M222.99M
Employees185146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRME has outperformed GLUE by 37.0 percentage points over the past year.
  • Monte Rosa Therapeutics is more profitable, keeping -31.2 cents of every revenue dollar as net income versus -4342.4 cents for Prime Medicine.
  • Monte Rosa Therapeutics grew revenue faster in its latest fiscal year (+63.54% vs +55.28%).

About Monte Rosa Therapeutics

GLUE stock →

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 185 employees

About Prime Medicine

PRME stock →

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees

GLUE vs PRME FAQ

Which is bigger, Monte Rosa Therapeutics or Prime Medicine?

Prime Medicine (PRME) is larger, with a market capitalization of $791.62M compared with $738.29M for Monte Rosa Therapeutics (GLUE).

Which stock has performed better over the past year, GLUE or PRME?

PRME returned -2.20% over the past 12 months, compared with -39.24% for GLUE (price return, excluding dividends). Past performance does not predict future results.

Are Monte Rosa Therapeutics and Prime Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons